Earnings call transcript: AGFA Gevaert Q2 2025 sees stock dip amid mixed results

AGFA Gevaert (AGFB) reported mixed Q2 2025 results, causing its stock to drop 4.9% to €1.08. Adjusted EBITDA decreased by €9 million, largely due to a €13 million gross profit decline in its struggling Radiology division, which faces accelerated market shifts. Conversely, free cash flow improved significantly by €45 million, and the Healthcare IT segment delivered strong growth, projected to achieve mid to high teen growth for the full year as it transitions to a subscription model. Despite subdued performance in Digital Print & Chemicals, management anticipates a positive net cash flow for 2025, with additional restructuring and cost savings planned for the second half.

Analysis

AGFA Gevaert's Q2 2025 results present a deeply contrasted operational picture, triggering a 4.9% stock price decline to €1.08. The company's performance is bifurcated between a rapidly deteriorating legacy business and a promising growth engine. The primary drag on performance is the Radiology Solutions segment, where gross profit fell by €13 million, contributing to a group-level adjusted EBITDA decrease of €9 million. Management attributes this to a faster-than-anticipated decline in the medical film market, especially in China, which is outpacing the company's cost-cutting measures. In stark contrast, the Healthcare IT division is performing strongly, with a projection for mid to high teen growth for the full year, driven by success in North America and a strategic shift to a subscription model, which now accounts for 58% of the division's Q2 revenue. While the Digital Print & Chemicals segment faces a subdued market, particularly for Green Hydrogen solutions, the company achieved a significant improvement in free cash flow, which rose by €45 million in the first half compared to the prior year. Management is addressing the challenges with a new restructuring program for Radiology and a corporate reorganization into two growth segments and one mature segment to enhance transparency and operational focus. The company's full-year outlook anticipates a positive net cash flow, a seasonally stronger second half, and approximately €10 million in cost savings in H2, though risks from the Radiology decline and the complex business model transition remain.

Key Decisions for Investors

• Investors should closely monitor the execution of the new restructuring program in the Radiology division and the realization of the projected €10 million in H2 cost savings, as these are critical to stabilizing group profitability against the segment's rapid decline.
• The investment thesis hinges on the Healthcare IT segment; its success should be gauged by tracking order intake growth and the increasing proportion of recurring revenue, even if the transition to a cloud model temporarily dampens reported top-line growth.
• Given the operational pressures and restructuring costs, the company's ability to maintain its positive free cash flow trajectory is a key metric to watch, validating management's control over working capital and overall financial discipline.
• While the stock's EV/EBITDA multiple of 3.24x suggests a potential value case, this valuation reflects significant execution risk, making it suitable primarily for investors with a high tolerance for volatility and a long-term focus on the company's strategic transformation.